| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 60 | 2025 | 1138 | 13.300 |
Why?
|
| Lung Neoplasms | 86 | 2025 | 2395 | 12.510 |
Why?
|
| Pneumonectomy | 26 | 2025 | 214 | 6.230 |
Why?
|
| Neoplasm Staging | 42 | 2025 | 2035 | 3.430 |
Why?
|
| Thoracic Surgery | 9 | 2025 | 50 | 3.120 |
Why?
|
| Surgeons | 6 | 2022 | 263 | 1.880 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2024 | 1398 | 1.830 |
Why?
|
| Osteopontin | 6 | 2013 | 48 | 1.800 |
Why?
|
| Thoracic Surgical Procedures | 5 | 2024 | 56 | 1.630 |
Why?
|
| Neoadjuvant Therapy | 9 | 2024 | 400 | 1.600 |
Why?
|
| Radiosurgery | 9 | 2021 | 299 | 1.580 |
Why?
|
| Humans | 143 | 2025 | 92339 | 1.460 |
Why?
|
| Physicians, Women | 5 | 2022 | 59 | 1.450 |
Why?
|
| Early Detection of Cancer | 6 | 2025 | 469 | 1.390 |
Why?
|
| Specialties, Surgical | 2 | 2021 | 70 | 1.310 |
Why?
|
| Thoracic Surgery, Video-Assisted | 6 | 2022 | 33 | 1.250 |
Why?
|
| Mesothelioma | 14 | 2023 | 327 | 1.180 |
Why?
|
| Adenocarcinoma | 11 | 2016 | 1191 | 1.180 |
Why?
|
| Pleural Neoplasms | 11 | 2016 | 201 | 1.060 |
Why?
|
| Small Cell Lung Carcinoma | 4 | 2023 | 119 | 1.010 |
Why?
|
| Esophagectomy | 5 | 2009 | 91 | 0.990 |
Why?
|
| Societies, Medical | 7 | 2025 | 596 | 0.920 |
Why?
|
| Disease Management | 3 | 2019 | 341 | 0.800 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2022 | 485 | 0.790 |
Why?
|
| Catheter Ablation | 6 | 2015 | 257 | 0.790 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2020 | 2685 | 0.780 |
Why?
|
| Thymectomy | 1 | 2022 | 31 | 0.780 |
Why?
|
| Jehovah's Witnesses | 1 | 2022 | 21 | 0.780 |
Why?
|
| Mass Screening | 4 | 2025 | 675 | 0.780 |
Why?
|
| Immunotherapy | 6 | 2023 | 725 | 0.750 |
Why?
|
| Myasthenia Gravis | 1 | 2022 | 83 | 0.750 |
Why?
|
| Radium | 4 | 2023 | 7 | 0.750 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 1575 | 0.720 |
Why?
|
| United States | 19 | 2025 | 7348 | 0.690 |
Why?
|
| Symptom Assessment | 1 | 2020 | 69 | 0.670 |
Why?
|
| Antibody Formation | 1 | 2020 | 171 | 0.660 |
Why?
|
| Esophageal Neoplasms | 4 | 2009 | 338 | 0.660 |
Why?
|
| Treatment Outcome | 15 | 2024 | 8730 | 0.660 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 302 | 0.650 |
Why?
|
| Female | 51 | 2025 | 47893 | 0.650 |
Why?
|
| Combined Modality Therapy | 11 | 2022 | 1733 | 0.640 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 2556 | 0.640 |
Why?
|
| Surgical Flaps | 3 | 2017 | 254 | 0.630 |
Why?
|
| Male | 46 | 2025 | 43927 | 0.620 |
Why?
|
| Aged | 32 | 2024 | 19951 | 0.610 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2016 | 1091 | 0.610 |
Why?
|
| Neoplasms, Second Primary | 5 | 2016 | 245 | 0.590 |
Why?
|
| Robotic Surgical Procedures | 2 | 2022 | 342 | 0.570 |
Why?
|
| Middle Aged | 36 | 2024 | 27043 | 0.570 |
Why?
|
| SEER Program | 4 | 2024 | 229 | 0.560 |
Why?
|
| Retrospective Studies | 16 | 2024 | 9689 | 0.530 |
Why?
|
| Salvage Therapy | 2 | 2017 | 234 | 0.520 |
Why?
|
| Probability | 1 | 2017 | 357 | 0.520 |
Why?
|
| Skin Ulcer | 1 | 2016 | 25 | 0.520 |
Why?
|
| Hyaluronan Receptors | 2 | 2013 | 38 | 0.490 |
Why?
|
| Frozen Sections | 1 | 2015 | 49 | 0.490 |
Why?
|
| Prognosis | 16 | 2021 | 3872 | 0.480 |
Why?
|
| Skin Transplantation | 1 | 2016 | 192 | 0.480 |
Why?
|
| Monitoring, Intraoperative | 1 | 2015 | 109 | 0.460 |
Why?
|
| Esophagus | 2 | 2006 | 107 | 0.460 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2012 | 142 | 0.440 |
Why?
|
| Pancoast Syndrome | 1 | 2013 | 2 | 0.430 |
Why?
|
| Radiopharmaceuticals | 3 | 2012 | 195 | 0.430 |
Why?
|
| Survival Rate | 10 | 2024 | 1926 | 0.430 |
Why?
|
| Radiation Injuries | 3 | 2024 | 160 | 0.430 |
Why?
|
| Fas Ligand Protein | 1 | 2013 | 50 | 0.410 |
Why?
|
| Adult | 28 | 2024 | 27538 | 0.400 |
Why?
|
| Positron-Emission Tomography | 5 | 2013 | 342 | 0.390 |
Why?
|
| Fluorine Radioisotopes | 1 | 2012 | 25 | 0.370 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 99 | 0.370 |
Why?
|
| Aged, 80 and over | 16 | 2023 | 6920 | 0.370 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 606 | 0.360 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 115 | 0.350 |
Why?
|
| Thoracic Neoplasms | 2 | 2024 | 66 | 0.350 |
Why?
|
| Bronchogenic Cyst | 1 | 2010 | 5 | 0.350 |
Why?
|
| Thoracic Diseases | 1 | 2010 | 27 | 0.340 |
Why?
|
| Soft Tissue Infections | 1 | 2010 | 26 | 0.340 |
Why?
|
| Thoracic Wall | 1 | 2010 | 24 | 0.340 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 1150 | 0.340 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 315 | 0.330 |
Why?
|
| Survival Analysis | 4 | 2019 | 1511 | 0.320 |
Why?
|
| Risk Assessment | 7 | 2022 | 2368 | 0.320 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 488 | 0.320 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2022 | 304 | 0.320 |
Why?
|
| Simulation Training | 2 | 2021 | 106 | 0.310 |
Why?
|
| Education, Medical, Graduate | 3 | 2020 | 411 | 0.310 |
Why?
|
| Lung Transplantation | 2 | 2024 | 350 | 0.300 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 547 | 0.290 |
Why?
|
| Health Status Disparities | 1 | 2011 | 201 | 0.290 |
Why?
|
| Perfusion | 3 | 2024 | 261 | 0.290 |
Why?
|
| Consensus | 4 | 2024 | 375 | 0.270 |
Why?
|
| Dumping Syndrome | 1 | 2006 | 5 | 0.250 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 2369 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 599 | 0.250 |
Why?
|
| Gastric Emptying | 1 | 2006 | 25 | 0.250 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 443 | 0.240 |
Why?
|
| Stomach | 1 | 2006 | 111 | 0.240 |
Why?
|
| Esophageal Diseases | 1 | 2005 | 26 | 0.230 |
Why?
|
| Patient Selection | 3 | 2020 | 690 | 0.230 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 329 | 0.230 |
Why?
|
| Transcription Factors | 1 | 2013 | 1689 | 0.230 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 315 | 0.230 |
Why?
|
| Patient Care Management | 2 | 2020 | 30 | 0.230 |
Why?
|
| Career Mobility | 1 | 2025 | 38 | 0.230 |
Why?
|
| Lung | 5 | 2024 | 1337 | 0.220 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2006 | 114 | 0.220 |
Why?
|
| Computer Simulation | 3 | 2021 | 1112 | 0.220 |
Why?
|
| Intubation, Intratracheal | 1 | 2006 | 152 | 0.220 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 121 | 0.220 |
Why?
|
| General Surgery | 1 | 2007 | 238 | 0.220 |
Why?
|
| Gastroesophageal Reflux | 1 | 2006 | 115 | 0.220 |
Why?
|
| Chemoradiotherapy | 3 | 2024 | 318 | 0.220 |
Why?
|
| Risk Factors | 5 | 2022 | 5706 | 0.220 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2024 | 37 | 0.220 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 3776 | 0.220 |
Why?
|
| Smoking | 2 | 2024 | 640 | 0.210 |
Why?
|
| Medicare | 2 | 2024 | 440 | 0.210 |
Why?
|
| Postoperative Complications | 4 | 2024 | 2453 | 0.210 |
Why?
|
| Thymoma | 1 | 2023 | 31 | 0.210 |
Why?
|
| Hamartoma | 1 | 2003 | 34 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2024 | 864 | 0.200 |
Why?
|
| Lymphatic Metastasis | 4 | 2010 | 498 | 0.200 |
Why?
|
| Thymus Neoplasms | 1 | 2023 | 43 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 127 | 0.200 |
Why?
|
| Negative-Pressure Wound Therapy | 2 | 2014 | 12 | 0.200 |
Why?
|
| Medical Oncology | 1 | 2007 | 393 | 0.200 |
Why?
|
| Radiotherapy, Conformal | 1 | 2023 | 85 | 0.200 |
Why?
|
| Chylothorax | 1 | 2022 | 8 | 0.200 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2002 | 30 | 0.200 |
Why?
|
| Faculty, Medical | 1 | 2025 | 198 | 0.200 |
Why?
|
| Chylous Ascites | 1 | 2022 | 9 | 0.200 |
Why?
|
| Frailty | 1 | 2024 | 86 | 0.200 |
Why?
|
| Time Factors | 4 | 2023 | 5429 | 0.190 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 1071 | 0.190 |
Why?
|
| Health Care Costs | 1 | 2023 | 247 | 0.180 |
Why?
|
| ErbB Receptors | 2 | 2022 | 498 | 0.180 |
Why?
|
| Steroids | 1 | 2022 | 173 | 0.180 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 47 | 0.180 |
Why?
|
| Funnel Chest | 1 | 2021 | 6 | 0.180 |
Why?
|
| Pneumothorax | 2 | 2020 | 50 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 105 | 0.180 |
Why?
|
| Lung Diseases | 1 | 2003 | 283 | 0.170 |
Why?
|
| Cohort Studies | 6 | 2024 | 2978 | 0.170 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 46 | 0.170 |
Why?
|
| Immunization, Passive | 1 | 2020 | 70 | 0.170 |
Why?
|
| Betacoronavirus | 2 | 2020 | 270 | 0.170 |
Why?
|
| Pandemics | 3 | 2021 | 808 | 0.170 |
Why?
|
| Critical Pathways | 1 | 2020 | 36 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2013 | 1901 | 0.160 |
Why?
|
| Sexual Harassment | 1 | 2019 | 9 | 0.160 |
Why?
|
| Career Choice | 1 | 2021 | 153 | 0.160 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 290 | 0.160 |
Why?
|
| Protein Isoforms | 2 | 2010 | 284 | 0.150 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2018 | 10 | 0.150 |
Why?
|
| Drainage | 1 | 2020 | 168 | 0.150 |
Why?
|
| Sexism | 1 | 2019 | 57 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 886 | 0.150 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 28 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 460 | 0.150 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 1593 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 167 | 0.140 |
Why?
|
| Thoracotomy | 1 | 2018 | 64 | 0.140 |
Why?
|
| Respiratory System | 1 | 2018 | 119 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 622 | 0.140 |
Why?
|
| Safety-net Providers | 1 | 2018 | 43 | 0.140 |
Why?
|
| Wound Closure Techniques | 1 | 2017 | 14 | 0.140 |
Why?
|
| Consolidation Chemotherapy | 1 | 2017 | 23 | 0.140 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 443 | 0.130 |
Why?
|
| Prosthesis-Related Infections | 1 | 2017 | 56 | 0.130 |
Why?
|
| Lymph Nodes | 2 | 2011 | 552 | 0.130 |
Why?
|
| Meta-Analysis as Topic | 4 | 2016 | 82 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1724 | 0.120 |
Why?
|
| Asbestos | 2 | 2012 | 22 | 0.120 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2015 | 72 | 0.120 |
Why?
|
| Apoptosis | 2 | 2013 | 1745 | 0.120 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 148 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 311 | 0.120 |
Why?
|
| Biopsy | 2 | 2016 | 1194 | 0.120 |
Why?
|
| Subcutaneous Emphysema | 1 | 2014 | 8 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1186 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 888 | 0.110 |
Why?
|
| Photochemotherapy | 1 | 1995 | 101 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 224 | 0.110 |
Why?
|
| Simian virus 40 | 4 | 1998 | 34 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2012 | 337 | 0.110 |
Why?
|
| Radiography | 2 | 2014 | 794 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2023 | 4471 | 0.110 |
Why?
|
| Receptor, EphB2 | 1 | 2013 | 3 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 569 | 0.110 |
Why?
|
| Peritoneum | 1 | 2013 | 56 | 0.100 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 48 | 0.100 |
Why?
|
| Microbiota | 1 | 2018 | 412 | 0.100 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 188 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2013 | 157 | 0.100 |
Why?
|
| Operative Time | 1 | 2013 | 156 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2729 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2013 | 794 | 0.100 |
Why?
|
| ROC Curve | 2 | 2012 | 786 | 0.100 |
Why?
|
| Epithelium | 1 | 2013 | 324 | 0.100 |
Why?
|
| Organ Preservation | 2 | 2024 | 131 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2007 | 171 | 0.090 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2012 | 129 | 0.090 |
Why?
|
| Cytokines | 3 | 2022 | 843 | 0.090 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2013 | 139 | 0.090 |
Why?
|
| Pain Management | 1 | 2013 | 154 | 0.090 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 129 | 0.090 |
Why?
|
| Biomarkers | 2 | 2016 | 1847 | 0.090 |
Why?
|
| Job Satisfaction | 1 | 2012 | 80 | 0.090 |
Why?
|
| Palliative Care | 1 | 2013 | 262 | 0.090 |
Why?
|
| Occupational Exposure | 1 | 2012 | 88 | 0.090 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2011 | 25 | 0.090 |
Why?
|
| Young Adult | 5 | 2021 | 6630 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2011 | 39 | 0.090 |
Why?
|
| Sternoclavicular Joint | 1 | 2010 | 2 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1399 | 0.090 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2010 | 8 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 41 | 0.090 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 41 | 0.090 |
Why?
|
| Cell Movement | 2 | 2013 | 801 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 696 | 0.090 |
Why?
|
| Ribonucleases | 1 | 2011 | 94 | 0.090 |
Why?
|
| Computer-Assisted Instruction | 1 | 2011 | 44 | 0.090 |
Why?
|
| Debridement | 1 | 2010 | 59 | 0.090 |
Why?
|
| Models, Anatomic | 1 | 2011 | 92 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2009 | 1052 | 0.090 |
Why?
|
| Functional Laterality | 1 | 2011 | 201 | 0.090 |
Why?
|
| Mutation | 1 | 2022 | 4212 | 0.080 |
Why?
|
| Joint Diseases | 1 | 2010 | 48 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2011 | 314 | 0.080 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 108 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2011 | 2671 | 0.080 |
Why?
|
| Necrosis | 1 | 2010 | 210 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2010 | 102 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2019 | 1084 | 0.080 |
Why?
|
| Tracheal Neoplasms | 1 | 2009 | 7 | 0.080 |
Why?
|
| Glomus Tumor | 1 | 2009 | 9 | 0.080 |
Why?
|
| Pain, Postoperative | 1 | 2012 | 274 | 0.080 |
Why?
|
| Sarcoidosis | 1 | 2010 | 72 | 0.080 |
Why?
|
| Chest Pain | 1 | 2009 | 46 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2010 | 431 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2025 | 1072 | 0.080 |
Why?
|
| Endosonography | 1 | 2010 | 100 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2010 | 124 | 0.080 |
Why?
|
| Opioid-Related Disorders | 1 | 2012 | 201 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 374 | 0.080 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 275 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 2 | 2005 | 45 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2013 | 2038 | 0.070 |
Why?
|
| MicroRNAs | 2 | 2011 | 575 | 0.070 |
Why?
|
| Wound Healing | 1 | 2010 | 371 | 0.070 |
Why?
|
| Length of Stay | 2 | 2020 | 790 | 0.070 |
Why?
|
| Microwaves | 1 | 2008 | 32 | 0.070 |
Why?
|
| Radiation Oncologists | 2 | 2018 | 15 | 0.070 |
Why?
|
| Chest Tubes | 2 | 2020 | 21 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 411 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2011 | 468 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 471 | 0.070 |
Why?
|
| DNA, Viral | 2 | 1998 | 253 | 0.070 |
Why?
|
| Sex Factors | 1 | 2011 | 1094 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 354 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 2 | 1998 | 45 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 455 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 1480 | 0.070 |
Why?
|
| Pulmonary Ventilation | 1 | 2006 | 33 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1179 | 0.060 |
Why?
|
| Sialoglycoproteins | 1 | 2006 | 31 | 0.060 |
Why?
|
| Carbonic Anhydrases | 1 | 2006 | 15 | 0.060 |
Why?
|
| Cognition | 1 | 2011 | 603 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2006 | 173 | 0.060 |
Why?
|
| Mediastinoscopy | 1 | 2005 | 5 | 0.060 |
Why?
|
| History, 21st Century | 2 | 2017 | 187 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 2 | 1998 | 183 | 0.060 |
Why?
|
| Thoracic Injuries | 1 | 2006 | 39 | 0.060 |
Why?
|
| California | 1 | 2006 | 156 | 0.060 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 9 | 0.060 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 475 | 0.060 |
Why?
|
| Esophagoplasty | 1 | 2005 | 9 | 0.060 |
Why?
|
| Anesthetics | 1 | 2005 | 53 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2005 | 122 | 0.060 |
Why?
|
| Risk | 1 | 2006 | 661 | 0.060 |
Why?
|
| Eligibility Determination | 1 | 2024 | 36 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 346 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2024 | 85 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 9495 | 0.050 |
Why?
|
| Incidence | 2 | 2022 | 1661 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2024 | 238 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 85 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 405 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2024 | 155 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2024 | 324 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2022 | 22 | 0.050 |
Why?
|
| Work-Life Balance | 1 | 2022 | 6 | 0.050 |
Why?
|
| Asthma | 1 | 2009 | 1003 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 317 | 0.050 |
Why?
|
| Transfection | 3 | 2011 | 901 | 0.040 |
Why?
|
| Leukocytes | 1 | 2022 | 212 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2021 | 110 | 0.040 |
Why?
|
| Oxygen | 1 | 2006 | 763 | 0.040 |
Why?
|
| Clinical Competence | 2 | 2020 | 807 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2003 | 444 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2021 | 133 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 68 | 0.040 |
Why?
|
| Epitopes | 1 | 2021 | 249 | 0.040 |
Why?
|
| Bioethics | 1 | 2020 | 35 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 199 | 0.040 |
Why?
|
| Risk Management | 1 | 2020 | 43 | 0.040 |
Why?
|
| Etoposide | 1 | 2020 | 206 | 0.040 |
Why?
|
| Child | 2 | 2022 | 7309 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 137 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 499 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 42 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 266 | 0.040 |
Why?
|
| Asbestosis | 2 | 1998 | 5 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 131 | 0.040 |
Why?
|
| Living Donors | 1 | 2022 | 342 | 0.040 |
Why?
|
| Sputum | 1 | 2018 | 35 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 128 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2022 | 531 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 130 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 1998 | 83 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2021 | 507 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1998 | 67 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 307 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1998 | 160 | 0.030 |
Why?
|
| Heart | 1 | 2021 | 584 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 259 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 807 | 0.030 |
Why?
|
| Liver | 1 | 2022 | 1228 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2012 | 902 | 0.030 |
Why?
|
| RNA, Antisense | 1 | 1996 | 15 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 2009 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 170 | 0.030 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 1996 | 18 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 1996 | 800 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2018 | 308 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 986 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 201 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 758 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 259 | 0.030 |
Why?
|
| Anniversaries and Special Events | 1 | 2016 | 15 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1745 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 2021 | 795 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 1998 | 274 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2017 | 123 | 0.030 |
Why?
|
| Chromosome Disorders | 1 | 1995 | 112 | 0.030 |
Why?
|
| Base Sequence | 2 | 1996 | 2319 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1995 | 155 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1995 | 168 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1995 | 131 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1995 | 153 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 317 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 2396 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3018 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 681 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 1995 | 384 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2018 | 550 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1805 | 0.030 |
Why?
|
| DNA Damage | 1 | 1995 | 381 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 299 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 324 | 0.030 |
Why?
|
| Cricetinae | 3 | 1998 | 538 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 1995 | 379 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1996 | 707 | 0.020 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2012 | 16 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2012 | 46 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 1995 | 504 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 289 | 0.020 |
Why?
|
| Fear | 1 | 2012 | 82 | 0.020 |
Why?
|
| Self Concept | 1 | 2012 | 135 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 562 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1180 | 0.020 |
Why?
|
| Thoracoscopes | 1 | 2011 | 2 | 0.020 |
Why?
|
| Surgical Staplers | 1 | 2011 | 10 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 331 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 126 | 0.020 |
Why?
|
| Dissection | 1 | 2011 | 43 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2011 | 101 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2010 | 37 | 0.020 |
Why?
|
| Motor Skills | 1 | 2011 | 79 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2011 | 63 | 0.020 |
Why?
|
| Carboplatin | 1 | 2011 | 321 | 0.020 |
Why?
|
| Mediastinum | 1 | 2010 | 47 | 0.020 |
Why?
|
| Affect | 1 | 2012 | 391 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 996 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 229 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 524 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1117 | 0.020 |
Why?
|
| Empyema | 1 | 2008 | 9 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2905 | 0.020 |
Why?
|
| Depression | 1 | 2012 | 526 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2006 | 1310 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 1998 | 115 | 0.020 |
Why?
|
| Plasmids | 2 | 1998 | 288 | 0.020 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2006 | 11 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 594 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2006 | 20 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1903 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 2005 | 35 | 0.020 |
Why?
|
| Tracheal Diseases | 1 | 2005 | 14 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 923 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1761 | 0.010 |
Why?
|
| Animals | 4 | 1998 | 28053 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2793 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2005 | 268 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 1505 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1998 | 91 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 1998 | 115 | 0.010 |
Why?
|
| Virus Replication | 1 | 1998 | 323 | 0.010 |
Why?
|
| Oxygenators | 1 | 1996 | 3 | 0.010 |
Why?
|
| Sarcoma, Ewing | 1 | 1996 | 43 | 0.010 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 1996 | 41 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1996 | 159 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 1996 | 74 | 0.010 |
Why?
|
| Safety | 1 | 1996 | 145 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1998 | 462 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 702 | 0.010 |
Why?
|
| Sarcoma | 1 | 1996 | 216 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1996 | 454 | 0.010 |
Why?
|
| Remission Induction | 1 | 1996 | 763 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1996 | 330 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1996 | 343 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1996 | 907 | 0.010 |
Why?
|
| Melanoma | 1 | 1996 | 482 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 1164 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 4066 | 0.010 |
Why?
|